Prediction of left ventricular reverse remodeling after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and β blockers in patients with idiopathic dilated cardiomyopathy

被引:8
|
作者
Matsumura, Yoshihisa [1 ]
Hoshikawa-Nagai, Eri [2 ]
Kubo, Toru [2 ]
Yamasaki, Naohito [2 ]
Kitaoka, Hiroaki [2 ]
Takata, Jun [3 ]
Doi, Yoshinori [4 ]
Sugiura, Tetsuro [1 ]
机构
[1] Kochi Univ, Kochi Med Sch, Dept Lab Med, Kochi, Oko Cho 7838505, Japan
[2] Kochi Univ, Kochi Med Sch, Dept Cardiol Neurol & Aging Sci, Kochi, Oko Cho 7838505, Japan
[3] Kochi Univ, Kochi Med Sch, Ctr Promote Creat Med Educ, Kochi, Oko Cho 7838505, Japan
[4] Chikamori Hosp, Kochi, Japan
基金
日本学术振兴会;
关键词
Remodeling; Atrial fibrillation; Cardiomyopathy; Heart failure; CHRONIC HEART-FAILURE; CLINICAL-OUTCOMES; EJECTION FRACTION; IMPROVEMENT; PROGNOSIS; ECHOCARDIOGRAPHY; CONJUNCTION; TACHYCARDIA; PREVALENCE; RECOVERY;
D O I
10.1186/s12947-015-0009-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Predictors of left ventricular reverse remodeling (LVRR) after therapy with angiotensin converting enzyme inhibitors or angiotensin-receptor blockers and beta blockers in patients with idiopathic dilated cardiomyopathy (IDC) remains unclear. Methods: We studied 44 patients with IDC who had been treated with the therapy. LVRR was defined as LV end-diastolic dimension <= 55 mm and fractional shortening >= 25% at the last echocardiogram. Results: During a mean follow-up period of 4.7 +/- 3.3 years, LVRR occurred in 34% (15/44) of the patients. We divided the patients into 2 groups: (1) patients with LVRR (n = 15); (2) patients without LVRR (n = 29). The presence of atrial fibrillation was 40% in patients with LVRR and 14% in those without (p = 0.067). Initial LV end-diastolic dimension was significantly smaller (62 +/- 6 vs. 67 +/- 6 mm, p = 0.033) in patients with LVRR than in those without. Initial LV end-diastolic dimension of 63.5 mm was an optimal cutoff value for predicting LVRR (sensitivity: 67%, specificity: 59%, area under the curve: 0.70, p = 0.030). When patients were further allocated according to initial LV end-diastolic dimension <= 63.5 mm with atrial fibrillation, the combined parameter was a significant predictor of LVRR by univariate logistic regression analysis (odds ratio, 5.78, p = 0.030) (sensitivity: 33%, specificity: 97%, p = 0.013). Conclusions: Combined information on LV end-diastolic dimension and heart rhythm at diagnosis is useful in predicting future LVRR in patients with IDC.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Prediction of left ventricular reverse remodeling after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and β blockers in patients with idiopathic dilated cardiomyopathy
    Yoshihisa Matsumura
    Eri Hoshikawa-Nagai
    Toru Kubo
    Naohito Yamasaki
    Hiroaki Kitaoka
    Jun Takata
    Yoshinori Doi
    Tetsuro Sugiura
    Cardiovascular Ultrasound, 13
  • [2] Effect of Left Ventricular Reverse Remodeling on Long-Term Prognosis After Therapy With Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers and β Blockers in Patients With Idiopathic Dilated Cardiomyopathy
    Hoshikawa, Eri
    Matsumura, Yoshihisa
    Kubo, Toru
    Okawa, Makoto
    Yamasaki, Naohito
    Kitaoka, Hiroaki
    Furuno, Takashi
    Takata, Jun
    Doi, Yoshinori L.
    AMERICAN JOURNAL OF CARDIOLOGY, 2011, 107 (07) : 1065 - 1070
  • [3] The Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Is Associated with the Recovered Ejection Fraction in Patients with Dilated Cardiomyopathy
    Enzan, Nobuyuki
    Matsushima, Shouji
    Ide, Tomomi
    Kaku, Hidetaka
    Tohyama, Takeshi
    Funakoshi, Kouta
    Higo, Taiki
    Tsutsui, Hiroyuki
    INTERNATIONAL HEART JOURNAL, 2021, 62 (04) : 801 - 810
  • [4] The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy
    Liu, Tao
    Zhou, Ping
    Jiang, Xin
    Wang, Na
    Shou, Jialing
    Fang, Yuqiang
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2023, 28 (01):
  • [5] Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: Anti-arrhythmic Drug for Arrhythmogenic Right Ventricular Cardiomyopathy
    Tu, Bin
    Wu, Lingmin
    Zheng, Lihui
    Liu, Shangyu
    Sheng, Lishui
    Liu, Limin
    Zhu, Zhenghui
    Yao, Yan
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [6] Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for the Prevention of Migraines
    Gales, Barry J.
    Bailey, Emilee K.
    Reed, Ashley N.
    Gales, Mark A.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (02) : 360 - 366
  • [7] Role of Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Aldosterone Antagonists in the Prevention of Atrial and Ventricular Arrhythmias
    Makkar, Kathy M.
    Sanoski, Cynthia A.
    Spinler, Sarah A.
    PHARMACOTHERAPY, 2009, 29 (01): : 31 - 48
  • [8] Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers after renal transplantation
    Morath, C.
    Schmied, B.
    Mehrabi, A.
    Weitz, J.
    Schmidt, J.
    Werner, J.
    Buchler, M. W.
    Morcos, M.
    Nawroth, P. P.
    Schwenger, V.
    Doehler, B.
    Opelz, G.
    Zeier, M.
    CLINICAL TRANSPLANTATION, 2009, 23 : 33 - 36
  • [9] Tolerability of Angiotensin-Receptor Blockers in Patients with Intolerance to Angiotensin-Converting Enzyme Inhibitors
    Caldeira, Daniel
    David, Claudio
    Sampaio, Cristina
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2012, 12 (04) : 263 - 277
  • [10] Angiotensin converting enzyme inhibitors and angiotensin receptor blockers
    Shrimpton, A. J.
    Walker, S. L. M.
    Ackland, G. L.
    BJA EDUCATION, 2020, 20 (11) : 362 - 367